Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel-carboplatin plus necitumumab vs paclitaxel-carboplatin in first-line stage IV squamous NSCLC
KCT0001107Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of necitumumab in Pulmonary squamous cell carcinoma, sponsored by Eli Lilly and Company. Started Mar 2013; status: active, not recruiting.
02
Drugs
necitumumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on KCT0001107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001107.